Urinary tract infections and bacterial prostatitis in men

Current Opinion in Infectious Diseases

Volumn 27, Issue 1, 2014, Pages 97-101

  Wagenlehner, Florian M E ^a   Weidner, Wolfgang ^a   Pilatz, Adrian ^a   Naber, Kurt G ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

bacterial prostatitis; prostate specific antigen; recurrent urinary tract infections

Indexed keywords

QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL LOAD; BLADDER WALL; CHRONIC PROSTATITIS; HUMAN; INFECTION RISK; NONHUMAN; PATHOPHYSIOLOGY; PROPHYLAXIS; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROSTATE SECRETION; REVIEW; TRANSRECTAL PROSTATE BIOPSY; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MALE; PROSTATITIS; RISK FACTORS; URINARY TRACT INFECTIONS;

EID: 84891834310     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000024     Document Type: Review

References (25)

1. Vorland LH, Carlson K, Aalen O. An epidemiological survey of urinary tract infections among outpatients in Northern Norway. Scand J Infect Dis 1985; 17:277-283. (Pubitemid 15236704)
2. Townes CL, Ali A, Gross N, et al. Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection. Prostate 2013; 73:1529-1537.
3. Stamm W. Urinary tract infections in young men. In: Bergan T, editor. Urinary tract infections. Basel: Karger; 1997.; pp. 46-47.
4. Ulleryd P. Febrile urinary tract infection in men. Int J Antimicrob Agents 2003; 22 (Suppl 2):89-93.
5. Millan-Rodriguez F, Palou J, Bujons-Tur A, et al. Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol 2006; 24:45-50. (Pubitemid 43298683)
6. Yoon BI, Kim S, Han DS, et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother 2012; 18:444-450.
7. Kunin C. Urinary tract infections. Detection, prevention and management. Philadelphia: Lea & Febiger; 1997.
8. Nicolle LE. Asymptomatic bacteriuria: when to screen and when to treat. Infect Dis Clin North Am 2003; 17:367-394. (Pubitemid 36760188)
9. Cek M, Tandogdu Z, Naber K, et al. Antibiotic prophylaxis in urology departments. Eur Urol 2013; 63:386-394.
10. Tandogdu Z, Cek M, Wagenlehner F, et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the Global Prevalence of Infections in Urology study. World J Urol 2013. [Epub ahead of print]
11. Toren P, Margel D, Kulkarni G, et al. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ 2013; 346:f2109.
12. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830-1834.
13. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183:963-968.
14. Loeb S, van den Heuvel S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61:1110-1114.
15. Wagenlehner FM, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and a prospective multinational multicentre prostate biopsy study. Eur Urol 2013; 63:521-527.
16. Steensels D, Slabbaert K, De Wever L, et al. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy: should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012; 18:575-581.
17. Abughosh Z, Margolick J, Goldenberg SL, et al. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol 2013; 189:1326-1331.
18. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum betalactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43-50.
19. Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev 2013; 8:CD009071.
20. Mulvey MA, Lopez-Boado YS, Wilson CL, et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 1998; 282:1494-1497. (Pubitemid 28538612)
21. Blango MG, Mulvey MA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 2010; 54:1855-1863.
22. Rosen DA, Hooton TM, Stamm WE, et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007; 4:e329.
23. Pouwels KB, Visser ST, Hak E. Effect of pravastatin and fosinopril on recurrent urinary tract infections. J Antimicrob Chemother 2013; 68:708-714.
24. Bishop BL, Duncan MJ, Song J, et al. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat Med 2007; 13:625-630. (Pubitemid 46828483)
25. Park DW, Chun BC, Kim JM, et al. Epidemiological and clinical characteristics of community-acquired severe sepsis and septic shock: a prospective observational study in 12 university hospitals in Korea. J Korean Med Sci 2012; 27:1308-1314.